CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Sanofi-Aventis U.S. LLC v. Emcure Pharmaceuticals Ltd.

1:17-cv-00070

Overview

Case Number 1:17-cv-00070
Filing Date 2017-01-25
Status Terminated
Termination Date 2017-04-28
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Heritage Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Larry R. Wood , Jr.

Blank Rome LLP

Tel: +1 (302) 425-6431

1201 North Market Street, Suite 800

Adam V. Orlacchio

Blank Rome LLP

Tel: +1 (302) 425-6431
Fax: +1 (302) 397-2156

1201 N. Market Street, Suite 800

Heritage Pharma Labs Inc. Operating Company

Represented By

2 Attorneys Listed

Larry R. Wood , Jr.

Blank Rome LLP

Tel: +1 (302) 425-6431

1201 North Market Street, Suite 800

Adam V. Orlacchio

Blank Rome LLP

Tel: +1 (302) 425-6431
Fax: +1 (302) 397-2156

1201 N. Market Street, Suite 800

Emcure Pharmaceuticals Ltd. Operating Company

Represented By

2 Attorneys Listed

Larry R. Wood , Jr.

Blank Rome LLP

Tel: +1 (302) 425-6431

1201 North Market Street, Suite 800

Adam V. Orlacchio

Blank Rome LLP

Tel: +1 (302) 425-6431
Fax: +1 (302) 397-2156

1201 N. Market Street, Suite 800

Plaintiff

Genzyme Corporation NPE (Individual / Inventor)

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Sanofi Operating Company

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Aventisub LLC Operating Company

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Sanofi-Aventis U.S. LLC Operating Company

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 9 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB 🇺🇸 US
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2017-01-12
1:17-cv-00040

Sanofi-Aventis U.S. LLC v. Par Pharmaceutical, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-12
1:17-cv-00039

Sanofi-Aventis U.S. LLC v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2017-01-11
1:17-cv-00031

Sanofi-Aventis U.S. LLC v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-10
1:17-cv-00027

Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited

Asserted Patent
Status: DED
U.S. District Court 2017-01-10
1:17-cv-00024

Sanofi-Aventis U.S. LLC v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-05
1:17-cv-00019

Sanofi-Aventis U.S. LLC v. Breckenridge Pharmaceutical, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-05
1:17-cv-00018

Sanofi-Aventis U.S. LLC v. Teva Pharmaceuticals USA, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-03
1:17-cv-00004

Sanofi-Aventis U.S. LLC v. IMPAX Laboratories, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-03
1:17-cv-00003

Sanofi-Aventis U.S. LLC v. Biocon Limited

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6794410
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Filed: 2002-04-01
Issued: 2004-09-21
Expired (Term Ended) +1639d PTA
Expires: 2026-09-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1639 days) / Cellect Scrutiny — Over 1639 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED - re 15 STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to April 25, 2017 filed by Aventisub LLC, Genzyme Corporatio...
Entry #— • 2017-04-10
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to April 25, 2017 - filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sanofi...
Entry #15 • 2017-04-07 Document →
Procedural / Extension Motion Pending
SO ORDERED - re 14 STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to April 10, 2017 filed by Aventisub LLC, Genzyme Corporatio...
Entry #— • 2017-03-22
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to April 10, 2017 - filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sanofi...
Entry #14 • 2017-03-20 Document →

Docket Entries

(35 total)
Pleading / Complaint

COMPLAINT filed against Emcure Pharmaceuticals Ltd., Heritage Pharma Labs Inc., Heritage Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2072179.) - filed by Sanofi-Aventis U.S. LLC, Aventisub LLC, Sanofi, Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(jcs) (Entered: 01/25/2017)

Entry #1 • 2017-01-25
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) (Entered: 01/25/2017)

Entry #2 • 2017-01-25
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: January 18, 2017. Date of Expiration of Patent: Sept. 12, 2026.Thirty Month Stay Deadline: 3/12/2020. (jcs) (Entered: 01/25/2017)

Entry #3 • 2017-01-25
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1. (jcs) (Entered: 01/25/2017)

Entry #4 • 2017-01-25
1

No Summons Issued. (jcs)

Entry #5 • 2017-01-25
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc